Towa Competitors

Delisted . USA . 
Stock . Towa Pharmaceutical Co
TWAPFDelisted Stock  USD 16.83  0.00  0.00%   
Towa Pharmaceutical competes with Kissei Pharmaceutical, SSY Group, Evotec SE, Nippon Shinyaku, and Trulieve Cannabis; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Towa Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Towa Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Towa Pharmaceutical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
16.8316.8316.83
Details
Intrinsic
Valuation
LowRealHigh
16.1116.1118.51
Details
Naive
Forecast
LowNextHigh
16.9716.9716.97
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
14.8016.9719.15
Details

Towa Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Towa Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Towa and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Towa Pharmaceutical does not affect the price movement of the other competitor.

High positive correlations

BIOGY
+ 0.84
GNMLF
BIOGY
+ 0.56
KSPHF
BIOGY
+ 0.56
TCNNF
GNMLF
+ 0.48
TCNNF
NPPNY
+ 0.41
EVOTF
GNMLF
+ 0.37
KSPHF
  

High negative correlations

GNMLF
- 0.94
EVOTF
BIOGY
- 0.83
EVOTF
GNMLF
- 0.47
NPPNY
TCNNF
- 0.45
EVOTF
EVOTF
- 0.43
KSPHF
CHIZF
- 0.26
EVOTF

Risk-Adjusted Indicators

There is a big difference between Towa Pink Sheet performing well and Towa Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Towa Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
KSPHF  0.98 (0.07) 0.00 (0.25) 0.00 
 0.00 
 0.00 
 0.00 
 42.55 
SWGHF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
LJUIF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
EVOTF  0.34  0.13  0.00  0.59  0.00 
 0.00 
 0.00 
 0.00 
 12.37 
NPPNY  5.50  2.04  0.15 (2.12) 6.25 
(14.51)
 8.72 
(3.11)
 189.41 
TCNNF  6.09  0.44  0.06  0.49  6.75 
(7.22)
 13.73 
(11.25)
 89.76 
GNMLF  0.79 (0.28) 0.00  0.65  0.00 
 0.00 
 0.00 
 0.00 
 14.69 
BIOGY  0.49 (0.07) 0.00 (0.52) 0.00 
 0.00 
 0.00 
(0.51)
 10.28 
CHIZF  0.76  0.05  0.00 (0.06) 0.00 
 0.00 
 0.00 
 0.00 
 47.86 
NPNKF  4.44 (0.18) 0.00  0.45  0.00 
 0.00 
 8.48 
(10.07)
 12.06 
All Fundamental Data

Towa Pharmaceutical Competitive Analysis

The better you understand Towa Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Towa Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Towa Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TWAPF KSPHF LJUIF EVOTF NPPNY TCNNF GNMLF BIOGY CHIZF NPNKF
 0.00 
 16.83 
Towa
 10.93 
 26.97 
Kissei
 42.86 
 0.40 
SSY
 13.62 
 8.01 
Evotec
 2.42 
 9.29 
Nippon
 0.13 
 7.88 
Trulieve
 0.00 
 1.14 
Genomma
 6.28 
 11.00 
Biogaia
 0.00 
 0.27 
China
 0.00 
 25.58 
Nippon
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very steady
Not too volatile
Very risky
Very risky
Very steady
Not too volatile
Out of control
Very steady
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Fair
Fair
Weak
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
High
Low
Low
Low
Moderate
Hazard
Low
Low
Hazard
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Not Rated
Current Ratio
2.49
6.27
2.01
3.57
5.41
3.28
1.67
9.97
2.08
5.61
Net Asset
N/A
238.09 B
10.71 B
2.24 B
219.94 B
3.41 B
21.54 B
2.21 B
36.39 B
219.94 B
Profit Margin
10.43
0.19
0.17
-0.26
0.18
-0.19
0.081
0.34
0.0843
0.18
EBITDA
31.73 B
20.26 B
1.01 B
316.63 M
38 B
276.51 M
2.84 B
476.89 M
2.74 B
38.01 B
Operating Margin
13.2
-0.0094
0.22
-0.0054
0.22
0.14
0.2
N/A
0.12
0.22
Current Valuation
56.49 B
487.73 M
1.82 B
2.68 B
3.4 B
2.48 B
1.09 B
719.05 M
3 B
3.4 B
Price To Book
0.01
0.58
2.24
2.28
2.52
0.83
1.38
4.8
0.99
3.68
Five Year Return
N/A
1.62
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
(618.9 M)
89.66 B
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
N/A
N/A
68.96 M
85.4 B
N/A
N/A
N/A
N/A
N/A
Beta
0.24
0.29
0.69
1.01
0.2
1.72
0.53
0.63
0.59
0.2
Number Of Employees
3.46 K
1.83 K
4.8 K
4.71 K
2.12 K
8 K
2.3 K
212
17.36 K
2.12 K
Shares Outstanding
49.21 M
46.12 M
2.97 B
176.95 M
269.41 M
159.64 M
1 B
100.98 M
5.04 B
67.35 M
Cash Flow From Operations
20.79 B
1.53 B
695.63 M
122.24 M
21.32 B
12.9 M
1.47 B
318.94 M
796.03 M
21.32 B
Annual Yield
N/A
0.0326
0.0233
N/A
0.017
N/A
0.0472
0.0335
0.0192
0.0157
Total Debt
79.68 B
1.64 B
1.69 B
326.34 M
2.6 B
469.38 M
3.83 B
N/A
2.81 B
N/A
Return On Equity
14.4
0.0648
0.18
-0.16
0.13
-0.14
0.13
0.19
0.0689
0.13
Z Score
N/A
N/A
0.6
7.2
0.6
1.2
N/A
N/A
N/A
N/A
Return On Asset
5.47
-0.0017
0.0836
-0.0012
0.0878
0.0479
0.0921
0.1
0.0331
0.0878
Book Value Per Share
N/A
4246.41
2.08
6.95
726.25
10.82
10.98
1.45
3.93
2905.0
Current Liabilities
N/A
N/A
N/A
26.45 M
20.57 B
N/A
N/A
N/A
N/A
N/A
Total Asset
N/A
238.09 B
10.71 B
2.24 B
219.94 B
3.41 B
21.54 B
2.21 B
36.39 B
219.94 B
Debt To Equity
0.63
0.008
0.41
0.38
0.014
0.47
0.51
0.01
0.22
N/A
Last Dividend Paid
0.44
68.0
0.13
N/A
59.0
N/A
0.38
N/A
0.06
59.0
Target Price
N/A
N/A
N/A
N/A
N/A
22.04
N/A
N/A
N/A
N/A
Shares Owned By Institutions
16.46
24.59
17.07
66.12
N/A
12.51
29.1
N/A
24.05
48.09
Market Capitalization
1.26 B
875.18 M
1.95 B
4.14 B
3.28 B
1.15 B
973.77 M
1.09 B
2.53 B
3.74 B
Price To Earning
8.48
15.2
20.77
347.66
19.16
23.96
11.09
34.09
7.93
22.05
Price To Sales
0.01
0.0132
0.3
4.35
0.0283
1.26
0.0526
8.56
0.15
0.0408
Net Income
16.95 B
12.92 B
785.53 M
215.51 M
24.99 B
18.03 M
1.31 B
373.58 M
1.93 B
24.99 B
Earnings Per Share
2.87
1.74
0.05
0.04
0.67
-0.29
0.07
0.26
0.04
2.67
Shares Owned By Insiders
47.82
25.87
57.88
9.86
N/A
8.76
29.0
N/A
35.73
5.1
Revenue
162.51 B
65.38 B
5.36 B
618.03 M
137.48 B
938.38 M
15.49 B
1.1 B
19.05 B
137.48 B
Working Capital
N/A
N/A
N/A
42.51 M
64.83 B
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
24.39 B
49.24 B
1.51 B
887.88 M
63.45 B
114.47 M
1.3 B
39.17 M
3.83 B
68.4 B
Cash Per Share
495.57
N/A
0.5
5.03
235.49
0.62
1.3
1.13
0.76
N/A
Gross Profit
65.45 B
31.24 B
3.17 B
151.54 M
87.29 B
607.32 M
9.56 B
801.93 M
11.83 B
87.29 B
Day Typical Price
16.83
28.07
0.5
7.69
9.13
7.91
1.14
11.0
0.27
25.58
Accumulation Distribution
N/A
0.11
0.43
0.12
0.0527
0.0311
N/A
N/A
N/A
N/A
Market Facilitation Index
N/A
3.31
0.3
0.96
0.49
0.25
N/A
N/A
N/A
N/A
Daily Balance Of Power
0.0
(1.00)
(1.00)
1.0
(0.47)
(0.04)
0.0
9.2 T
0.0
0.0
Period Momentum Indicator
N/A
(3.31)
(0.30)
0.96
(0.23)
(0.01)
N/A
0.65
N/A
N/A
Rate Of Daily Change
1.0
0.89
0.57
1.14
0.98
1.0
1.0
1.06
1.0
1.0
Day Median Price
16.83
28.63
0.55
7.53
9.05
7.93
1.14
11.0
0.27
25.58
Price Action Indicator
N/A
(3.31)
(0.30)
0.96
0.13
(0.05)
N/A
0.33
N/A
N/A
Coefficient Of Variation
2927.17
(10,643)
N/A
907.05
943.36
2051.06
(767.43)
(3,508)
12940.4
(3,275)
Mean Deviation
1.52
0.9842
N/A
0.3367
5.5
6.09
0.7927
0.4926
0.7566
4.44
Jensen Alpha
0.395
(0.07)
N/A
0.1255
2.04
0.4367
(0.28)
(0.07)
0.0531
(0.18)
Total Risk Alpha
(0.56)
(0.53)
N/A
(0.01)
(0.03)
(0.64)
(0.58)
(0.24)
(0.43)
(0.93)
Sortino Ratio
N/A
N/A
N/A
N/A
0.1469
0.0604
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
N/A
166.56
53.26
N/A
N/A
N/A
N/A
Standard Deviation
7.52
4.42
N/A
1.4
18.69
10.79
2.39
1.68
4.2
6.69
Kurtosis
37.46
27.1
N/A
64.69
50.61
21.4
28.83
17.28
32.76
1.47
Potential Upside
N/A
N/A
N/A
N/A
8.72
13.73
N/A
N/A
N/A
8.48
Treynor Ratio
(0.13)
(0.25)
N/A
0.5916
(2.12)
0.4881
0.6459
(0.52)
(0.06)
0.4482
Maximum Drawdown
84.06
42.55
N/A
12.37
189.41
89.76
14.69
10.28
47.86
12.06
Variance
56.5
19.52
N/A
1.95
349.15
116.53
5.73
2.82
17.65
44.78
Market Risk Adjusted Performance
(0.12)
(0.24)
N/A
0.6016
(2.11)
0.4981
0.6559
(0.51)
(0.05)
0.4582
Risk Adjusted Performance
0.033
0.0018
N/A
0.0823
0.084
0.0436
(0.08)
(0.01)
0.0138
(0.01)
Skewness
3.3
2.09
N/A
8.0
6.36
3.53
(5.24)
(1.31)
0.764
(0.41)
Semi Deviation
N/A
N/A
N/A
N/A
6.25
6.75
N/A
N/A
N/A
N/A
Information Ratio
0.0228
(0.03)
N/A
0.0492
0.1014
0.0409
(0.17)
(0.08)
(0.01)
(0.04)
Value At Risk
N/A
N/A
N/A
N/A
(3.11)
(11.25)
N/A
(0.51)
N/A
(10.07)
Expected Short fall
N/A
N/A
N/A
N/A
(14.51)
(7.22)
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
N/A
12.91
7.3
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
N/A
39.03
45.53
N/A
N/A
N/A
N/A

Towa Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Towa Pharmaceutical Competition

Towa Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Towa Pharmaceutical in relation to its competition. Towa Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Towa Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Towa Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Towa Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Towa Pharmaceutical position

In addition to having Towa Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run USD Crypto Fund Thematic Idea Now

USD Crypto Fund
USD Crypto Fund Theme
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Towa Pink Sheet

If you are still planning to invest in Towa Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Towa Pharmaceutical's history and understand the potential risks before investing.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY